Table 4

HF medication in the study population, divided into quartiles based on BNP
BNP quartile 1 2 3 4 p value
Range (ng/L) 10-51 52-102 103-191 192-4200
(n = 100) (n = 101) (n = 101) (n = 100)
ACE inhibitors/ARBs n (%) 14 (14) 20 (19.8) 20 (19.8) 28 (28) 0.11
Beta-blockers n (%) 14 (14) 31 (30.7) 45 (44.6) 54 (54) <0.001
a, b, c, e
Spironolactone n (%) 9 (9) 4 (4) 7 (6.9) 7 (7) 0.56
Digoxin n (%) 2 (2) 1 (1) 13 (12.9) 14 (14) <0.001
b, c, d, e
Furosemide/loop diuretics n (%) 27 (27) 39.6 (40) 36 (35.6) 50 (50) 0.009
c
Loop diuretics with simultaneous ACE inhibitor/ARB treatment n (%) 6 (6) 15 (14.9) 13 (12.9) 20 (20) 0.034
c

Significant difference between BNP quartiles 1–4, is presented as:

1 and 2: a.

1 and 3: b.

1 and 4: c.

2 and 3: d.

2 and 4: e.

3 and 4: f.

Bolmsjö et al.

Bolmsjö et al. BMC Geriatrics 2013 13:118   doi:10.1186/1471-2318-13-118

Open Data